EMEA-002146-PIP01-17-M01

Key facts

Invented name
Ibrance
Active substance
palbociclib
Therapeutic area
Oncology
Decision number
P/0203/2019
PIP number
EMEA-002146-PIP01-17-M01
Pharmaceutical form(s)
  • Age-appropriate oral liquid dosage form
  • Capsule (hard)
Condition(s) / indication(s)
Treatment of Ewing sarcoma
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europe MA EEIG

Tel. +44 1304 6466 07
E-mail: PIP_enquiries@pfizer.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating